Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common dewormer stop a rare, deadly liver parasite?

NCT ID NCT07182305

Disease control Sponsor: Ministry of Health, Kyrgyzstan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 2 trial tested the drug albendazole in 194 people with early-stage alveolar echinococcosis, a parasitic liver disease that is nearly always fatal within 10-15 years if untreated. Participants took albendazole twice daily and were monitored with ultrasound to see if their liver lesions shrank, calcified, or stopped growing. The goal is to see if early treatment can control the parasite and extend life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
albendazole
What this could lead to
If successful, this could confirm that early albendazole treatment controls the parasite and prevents disease progression, potentially allowing patients to live a normal lifespan.
What could go wrong
This is a small, completed Phase 2 trial in one region. Albendazole is parasitostatic, not curative, and lifelong treatment may be needed. Results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

194 people

The number who actually took part.

Started

May 2017

Finished

Jul 2023

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presence of lesion diagnosed by ultrasound that is consistent with early stage alveolar echinococcosis. Lesion less than 3 cm in diameter Exclusion Criteria: * Absence of lesion. Large lesion requiring surgical treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alveolar echinococcosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alveolar echinococcosis echinococcosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alveolar echinococcosis

Contacts and locations

Locations

  • Department of disease prevention and sanitary - epidemiological surveillance

    Bishkek, Kyrgyzstan